Reference only — not a dosing recommendation.
Product-, indication-, and jurisdiction-specific — see the monograph
- Cushing's disease (Signifor SC): 0.6 mg SC BID initial, titrate to 0.9 mg SC BID based on tolerability and response. Acromegaly (Signifor LAR): 40 mg IM q4wk initial, maximum 60 mg. Cushing's disease (Signifor LAR): 10 mg IM q4wk initial, maximum 40 mg.
Studied in trials — not a recommended dose
- Phase 3 Cushing's: 0.6–0.9 mg SC BID.
- PAOLA: pasireotide LAR 40–60 mg IM q4wk.
- Efficacy beyond 2 years in controlled settings.
- Optimal sequencing after surgery or radiation.
- No established or recommended human dose for unapproved indications.
Pasireotide — secção de evidência de dose e administração da monografia